Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any fatal multiple mitochondrial dysfunctions syndrome in which the cause of the disease is a mutation in the NFU1 gene.
Features include always present findings: Lethargy, Increased urine alpha-ketoglutarate concentration, Decreased activity of mitochondrial respiratory chain, and Alpha-aminoadipic aciduria and others; and very common findings: Failure to thrive and Hyperglycinemia. 31 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 7 | Loss of previously acquired skills (developmental regression), Leukoencephalopathy, Global developmental delay |
NFU1 encodes NFU1 iron-sulfur cluster scaffold (254 aa). Iron-sulfur cluster scaffold protein which can assemble [4Fe-4S] clusters and deliver them to target proteins Highest expression in Artery Tibial (39.9 TPM) and Adipose Subcutaneous (36.7 TPM).
Multiple mitochondrial dysfunctions syndrome 1 is associated with mutations in the NFU1 gene on chromosome 2.
The NFU1 protein participates in LIAS synthesizes lipoyl-GCSH, FXN:NFS1:ISD11:ISCU assembles 2Fe-2S iron-sulfur cluster, and Mitochondrial iron-sulfur cluster biogenesis pathways.
NFU1 is classified as a druggable target with score 0.0.
Genetic testing for NFU1 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 25 always present features, 2 very common features, 4 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for multiple mitochondrial dysfunctions syndrome 1.
3 publications have been identified in PubMed for multiple mitochondrial dysfunctions syndrome 1. Research spans Review / Meta-Analysis (33%), Basic Science / Preclinical (33%), and Epidemiology / Natural History (33%).
DiFalco CR (2026). [PMID: 42192213](https://pubmed.ncbi.nlm.nih.gov/42192213/). *Am J Med Genet A*. [Review / Meta-Analysis]
Liu S (2025). [PMID: 40233434](https://pubmed.ncbi.nlm.nih.gov/40233434/). *Biochemical and biophysical research communications*. [Basic Science / Preclinical]
Wang L (2025). [PMID: 40186305](https://pubmed.ncbi.nlm.nih.gov/40186305/). *Journal of cardiothoracic surgery*. [Epidemiology / Natural History]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 3:01 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Lab test results | 6 | Increased urine alpha-ketoglutarate concentration, Decreased activity of mitochondrial respiratory chain, Decreased activity of mitochondrial complex II |
Lungs and breathing | 4 | Decreased activity of mitochondrial respiratory chain, Respiratory failure, High blood pressure in lung arteries (pulmonary arterial hypertension) |
Muscles | 2 | Muscle weakness, Axial hypotonia |
Growth and development | 1 | Failure to thrive |
Metabolism | 1 | Episodic metabolic acidosis |
Bones and joints | 1 | Severe backward arching of the body (opisthotonus) |
Head and neck | 1 | Facial paralysis |
Digestive system | 1 | Feeding difficulties |
Heart and blood vessels | 1 | High blood pressure in lung arteries (pulmonary arterial hypertension) |
AI-curated news mentioning multiple mitochondrial dysfunctions syndrome 1
Updated May 26, 2026
A recent case study highlights multiple mitochondrial dysfunctions syndrome 1, contributing to the understanding of this rare condition. The literature review provides insights into clinical manifestations and potential therapeutic approaches.